Ga-68-DOTA-peptides in the Diagnosis of NET

被引：24

作者：

Ambrosini, Valentina ^{[1
]}

Fanti, Stefano ^{[1
]}

机构：

[1] Univ Bologna, S Orsola Malpighi Univ Hosp, Nucl Med, I-40138 Bologna, Italy

来源：

PET CLINICS | 2014年 / 9卷 / 01期

关键词：

Ga-68-DOTA-peptides; PET/CT; Neuroendocrine tumors; Somatostatin receptors;

D O I：

10.1016/j.cpet.2013.08.007

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Ga-68-DOTA-peptides are increasingly used for the detection of neuroendocrine tumors (NET) in clinical trials in Europe. They have been proved accurate for the detection of NET lesions (at primary and metastatic sites) and no adverse effects were recorded. Moreover, providing data on somatostatin receptors expression on NET cells, Ga-68-DOTA-peptides PET/CT is becoming a fundamental procedure to be performed before starting therapy and to guide treatment with either hot or cold somatostatin analogues. The easy and economic synthesis process is another advantage that is supporting its clinical use even in centers without an on-site cyclotron.

引用

页码：37 / +

页数：7

共 27 条

[1]

Krenning E.P., Kwekkeboom D.J., Bakker W.H., Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-and [123I-Tyr3]-octreotide: The Rotterdam experience with more than 1000 patients, Eur J Nucl Med, 20, pp. 716-731, (1993)

[2]

Kowalski J., Henze M., Schuhmacher J., Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D-Phe1-Tyr3-octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors, Mol Imaging Biol, 5, pp. 42-48, (2003)

[3]

Buchmann I., Henze M., Engelbrecht S., Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours, Eur J Nucl Med Mol Imaging, 34, 10, pp. 1617-1626, (2007)

[4]

Antunes P., Ginj M., Zhang H., Are radiogallium-labelled DOTA-conjugated somatostatin analogues superior to those labelled with other radiometals?, Eur J Nucl Med Mol Imaging, 34, 7, pp. 982-993, (2007)

[5]

Reubi J.C., Peptide receptors as molecular targets for cancer diagnosis and therapy, Endocr Rev, 24, 4, pp. 389-427, (2003)

[6]

Reubi J.C., Waser B., Concomitant expression of several peptide receptors in neuroendocrine tumors: Molecular basis for in vivo multireceptor tumour targeting, Eur J Nucl Med Mol Imaging, 30, 5, pp. 781-793, (2003)

[7]

Gabriel M., Decristoforo C., Kendler D., 68Ga-DOTA-Tyr3-octreotide PET in neuroendocrine tumors: Comparison with somatostatin receptor scintigraphy and CT, J Nucl Med, 48, 4, pp. 508-518, (2007)

[8]

Ambrosini V., Campana D., Tomassetti P., 68Ga-labelled peptides for diagnosis of gastroenteropancreatic NET, Eur J Nucl Med Mol Imaging, 39, SUPPL. 1, (2012)

[9]

Virgolini I., Ambrosini V., Bomanji J.B., Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE, Eur J Nucl Med Mol Imaging, 37, 10, pp. 2004-2010, (2010)

[10]

Poeppel T.D., Binse I., Petersenn S., 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors, J Nucl Med, 52, 12, pp. 1864-1870, (2011)

← 1 2 3 →